Illumina: The Indestructible Foundation of Gene Code Decoding

Illumina secures highly profitable, recurring revenues through the sale of gene sequencing machines and the essential consumables required for them. As the global market leader with a market share of around 80%, the company benefits from enormous economies of scale and high switching costs for its customers. The increasing use of genomic decoding in medical practice, especially in cancer therapies and early detection, ensures long-term tailwinds for Illumina. Illumina (NASDAQ: ILMN) has been considered the undisputed market leader in genomic...